Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.

Journal: Frontiers in immunology
Published Date: Jan 17, 2024

Abstract

BACKGROUND: Bladder cancer (BCa) is a common malignancy of the urinary tract. Due to the high heterogeneity of BCa, patients have poor prognosis and treatment outcomes. Immunotherapy has changed the clinical treatment landscape for many advanced malignancies, opening new avenues for the precise treatment of malignancies. However, effective predictors and models to guide clinical treatment and predict immunotherapeutic outcomes are still lacking.

Authors

  • Yan Xu
    Department of Nephrology, Suzhou Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, China.
  • Xiaoyu Sun
    Department of Radiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Guangxu Liu
    Department of Urology, The First Hospital of China Medical University, Shenyang, China.
  • Hongze Li
    Department of Urology, The First Hospital of China Medical University, Shenyang, China.
  • Meng Yu
    Department of Laboratory Animal Science, China Medical University, Liaoning, Shenyang, China.
  • Yuyan Zhu
    Department of Urology, The First Hospital of China Medical University, Shenyang, China.

Keywords

External Resources

Popular Topics
Recent Journals